在西北阿姆哈拉地区的慢性心力衰竭患者中,药物不服药及其预测因素
Getachew Yitayew Tarekegn1, Fisseha Nigussie Dagnew2, Tilaye Arega Moges2
1Department of Clinical Pharmacy, Pharmacy Education and Clinical Services Directorate, College of Health Sciences, Debre Tabor University, PO Box 272, Debre Tabor, Ethiopia. gtsehay22@gmail.com.
Scientific reports
|June 6, 2025
概括
不坚持治疗影响了17.7%的慢性心力衰竭 (CHF) 患者. 不定期的后续检查和像骨质疏松这样的症状显著增加了这种风险,影响了患者的结果.
科学领域:
- 心脏病学 心脏病学
- 公共卫生 公共卫生
- 临床药房 临床药房
背景情况:
- 心力衰竭 (HF) 影响全球超过6400万,需要有效的治疗坚持.
- 坚持是改善生活质量和减少在渐进性HF条件下住院的关键.
研究的目的:
- 为了确定慢性心力衰竭 (CHF) 患者不坚持的患病率.
- 为了确定与成年CHF患者进行后续护理中不遵守相关的因素.
主要方法:
- 一项多中心前性横截面研究与360名成年CHF患者进行.
- 数据通过预先测试的抽象格式收集,并量化了不遵守率.
- 多变量逻辑回归确定了不遵守的预测因素,随着几率比率 (OR) 测量效应大小.
主要成果:
- 这项研究发现,在心血管疾病患者队列中,失效率为17.7%.
- 不定期的后续检查 (AOR 1.11),骨折 (AOR 5.02) 和肺部 (AOR 12.00) 与增加的不坚持有显著联系.
- 患有骨质疏松症的患者和不规则随访的患者表现出明显更高的不良坚持率.
结论:
- 不遵守是CHF管理的一个重要问题,患病率为17.7%.
- 骨质疏松和不规则的后续检查是不良坚持的关键预测因素.
- 通过持续的随访和有效的症状管理来提高药物坚持,对于改善患者的治疗结果和减少医疗负担至关重要.
相关概念视频
Heart Failure VI: Adjunct Therapies
39
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
39
Heart Failure V: Medical Management
34
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
34
Heart Failure VII: Nursing Interventions
147
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
147
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
526
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
526
Heart Failure Drugs: β-Blockers
446
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
446
Heart Failure Drugs: Diuretics
505
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
505


